Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with colorectal cancer that has spread to other parts of the body (confirmed by a tissue test), and whose cancer has continued to grow after receiving standard treatments, or who are not suitable candidates for those treatments.
• People with a life expectancy of at least 3 months.
• People aged 18 years or older, of any gender.
• People with a good general health and activity level, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work).
• People whose cancer can be measured on a scan (CT or MRI) according to standard guidelines.
• People whose blood counts, liver, and kidney functions fall within acceptable ranges as determined by blood and urine tests (confirm with trial site for specific values).
• People who are able to receive iodine-based contrast dye during a CT scan (i.e., no known allergy or contraindication).
• Women who could become pregnant must have a negative pregnancy test within 14 days before starting the study treatment, and both men and women must use adequate contraception during the study where applicable.
• People who have read, understood, and signed an informed consent form before joining.
• People who, in the opinion of the trial doctor, are able to follow the study schedule and requirements.
• People who are registered with a national health care system.

Who may not be able to join:

• People who have been diagnosed with another cancer within the past 2 years (except certain skin cancers or early-stage cervical or bladder cancers that have been fully treated).
• People who are currently taking part in another clinical trial or are still within a required waiting period after a previous trial.
• People facing personal, family, social, or geographical circumstances that could make it difficult to follow the trial schedule and requirements.
• People who are under legal guardianship or whose personal freedom is restricted.
• People who have previously been treated with the study drug regorafenib, or with certain other anti-cancer drugs that target blood vessel growth (other than bevacizumab or aflibercept).
• People who have received another experimental treatment within 28 days before joining the trial (except aspirin).
• People who are currently receiving, or have received within the past 3 weeks, other systemic cancer treatments such as chemotherapy, immunotherapy, hormone therapy, or targeted therapy.
• People who regularly take certain medications that are known to interact with the study drugs, including some epilepsy medications or a specific antiviral drug called brivudine (confirm with trial site for the full list).
• People who have a complete deficiency of a specific enzyme called DPD (dihydropyrimidine dehydrogenase), which affects how the body processes certain chemotherapy drugs.
• People with a known allergy or serious reaction to any of the study drugs or their ingredients, including a history of severe reactions to a type of chemotherapy called fluoropyrimidines, aspirin-triggered asthma, or a rare condition called mastocytosis.
• People who still have unresolved side effects (above a mild level) from previous cancer treatments, with some exceptions such as hair loss, an underactive thyroid, or mild nerve damage from a prior treatment.
• People who are unable to swallow tablets or capsules, or who have a condition affecting the absorption of food or medication.
• People with serious heart, lung, kidney, or other organ problems, including uncontrolled high blood pressure, recent heart attack (within 6 months), unstable chest pain, significant heart failure, serious lung disease, active infection, dehydration, fluid build-up causing breathing difficulty, or a blocked urinary tract.
• People who have had significant bleeding events, bowel perforation, an abdominal abscess, a fistula, or active stomach or bowel bleeding within the past 4 to 6 months (timeframe depends on the specific condition — confirm with trial site).
• People who have a serious unhealed wound, an active stomach ulcer, or an untreated broken bone.
• People who have had major surgery, an open biopsy, or a significant injury within 28 days before starting the trial.
• People who are expected to need surgery within the first month of treatment, or any procedure that could affect the timing of the study drug during that period.
• People with a known history of HIV, or active or ongoing hepatitis B or C requiring antiviral treatment.
• People who have received a yellow fever vaccine within 28 days before joining the trial.
• People who have had an organ transplant.
• People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.